CL2020001290A1 - Método para el tratamiento de enfermedades gastrointestinales con tradipitant. - Google Patents
Método para el tratamiento de enfermedades gastrointestinales con tradipitant.Info
- Publication number
- CL2020001290A1 CL2020001290A1 CL2020001290A CL2020001290A CL2020001290A1 CL 2020001290 A1 CL2020001290 A1 CL 2020001290A1 CL 2020001290 A CL2020001290 A CL 2020001290A CL 2020001290 A CL2020001290 A CL 2020001290A CL 2020001290 A1 CL2020001290 A1 CL 2020001290A1
- Authority
- CL
- Chile
- Prior art keywords
- tradipitant
- treatment
- gastrointestinal diseases
- gastric motility
- receptor antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762587681P | 2017-11-17 | 2017-11-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020001290A1 true CL2020001290A1 (es) | 2020-11-13 |
Family
ID=64734107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020001290A CL2020001290A1 (es) | 2017-11-17 | 2020-05-15 | Método para el tratamiento de enfermedades gastrointestinales con tradipitant. |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20200030307A1 (enExample) |
| EP (1) | EP3710000B1 (enExample) |
| JP (1) | JP7306614B2 (enExample) |
| KR (2) | KR102864285B1 (enExample) |
| CN (2) | CN119074729A (enExample) |
| AU (1) | AU2018367623B2 (enExample) |
| BR (1) | BR112020009520A2 (enExample) |
| CA (1) | CA3081582A1 (enExample) |
| CL (1) | CL2020001290A1 (enExample) |
| DK (1) | DK3710000T3 (enExample) |
| ES (1) | ES3032138T3 (enExample) |
| FI (1) | FI3710000T3 (enExample) |
| HR (1) | HRP20250615T1 (enExample) |
| HU (1) | HUE071527T2 (enExample) |
| IL (1) | IL274541B2 (enExample) |
| MX (1) | MX2020005167A (enExample) |
| PT (1) | PT3710000T (enExample) |
| SI (1) | SI3710000T1 (enExample) |
| WO (1) | WO2019099883A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016141341A1 (en) * | 2015-03-04 | 2016-09-09 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| US20210228555A1 (en) * | 2018-06-08 | 2021-07-29 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| CN111918701B (zh) * | 2018-09-28 | 2024-08-02 | 万达制药公司 | 曲地匹坦在晕动病中的用途 |
| WO2020117811A1 (en) | 2018-12-03 | 2020-06-11 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| JP7791832B2 (ja) | 2020-03-26 | 2025-12-24 | バンダ・ファーマシューティカルズ・インコーポレイテッド | トラジピタントによる下気道感染症の治療 |
| WO2023019084A1 (en) | 2021-08-12 | 2023-02-16 | Vanda Pharmaceuticals Inc. | Treatment of gastric accommodation with tradipitant |
| US20240350469A1 (en) | 2021-08-31 | 2024-10-24 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| JP2025542424A (ja) | 2022-12-21 | 2025-12-25 | バンダ・ファーマシューティカルズ・インコーポレイテッド | トラジピタントによる処置の方法 |
| EP4599831A1 (en) | 2024-02-09 | 2025-08-13 | Vanda Pharmaceuticals Inc. | Treatment of gastroparesis with tradipitant |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003230829B8 (en) | 2002-04-26 | 2008-12-11 | Eli Lilly And Company | Triazole derivatives as tachykinin receptor antagonists |
| KR100848407B1 (ko) * | 2003-10-24 | 2008-07-28 | 일라이 릴리 앤드 캄파니 | ｛2-[1-(3,5-비스-트리플루오로메틸벤질)-5-피리딘-4-일-1ｈ-[1,2,3]트리아졸-4-일]-피리딘-3-일｝-(2-클로로페닐)-메탄온의 신규 결정질 형태 |
| WO2008079600A1 (en) * | 2006-12-20 | 2008-07-03 | Eli Lilly And Company | Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
| HRP20140759T1 (hr) * | 2009-11-18 | 2014-10-24 | Helsinn Healthcare S.A. | Kompozicije za lijeäśenje središnje posredovane muäśnine i povraä†anja |
| WO2016141341A1 (en) * | 2015-03-04 | 2016-09-09 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| CA3009325A1 (en) | 2015-12-22 | 2017-06-29 | Takeda Pharmaceutical Company Limited | Tripartite modulators of endosomal g protein-coupled receptors |
-
2018
- 2018-11-16 HR HRP20250615TT patent/HRP20250615T1/hr unknown
- 2018-11-16 KR KR1020207014967A patent/KR102864285B1/ko active Active
- 2018-11-16 EP EP18821773.1A patent/EP3710000B1/en active Active
- 2018-11-16 PT PT188217731T patent/PT3710000T/pt unknown
- 2018-11-16 MX MX2020005167A patent/MX2020005167A/es unknown
- 2018-11-16 WO PCT/US2018/061593 patent/WO2019099883A1/en not_active Ceased
- 2018-11-16 FI FIEP18821773.1T patent/FI3710000T3/fi active
- 2018-11-16 CN CN202411421827.XA patent/CN119074729A/zh active Pending
- 2018-11-16 SI SI201831236T patent/SI3710000T1/sl unknown
- 2018-11-16 CN CN201880073477.9A patent/CN111343981A/zh active Pending
- 2018-11-16 KR KR1020257031352A patent/KR20250140655A/ko active Pending
- 2018-11-16 AU AU2018367623A patent/AU2018367623B2/en active Active
- 2018-11-16 JP JP2020527780A patent/JP7306614B2/ja active Active
- 2018-11-16 BR BR112020009520-6A patent/BR112020009520A2/pt not_active Application Discontinuation
- 2018-11-16 DK DK18821773.1T patent/DK3710000T3/da active
- 2018-11-16 CA CA3081582A patent/CA3081582A1/en active Pending
- 2018-11-16 ES ES18821773T patent/ES3032138T3/es active Active
- 2018-11-16 HU HUE18821773A patent/HUE071527T2/hu unknown
- 2018-11-16 IL IL274541A patent/IL274541B2/en unknown
-
2019
- 2019-10-01 US US16/590,048 patent/US20200030307A1/en not_active Abandoned
-
2020
- 2020-05-15 CL CL2020001290A patent/CL2020001290A1/es unknown
- 2020-12-11 US US17/119,349 patent/US20210093621A1/en not_active Abandoned
-
2021
- 2021-07-08 US US17/370,211 patent/US20210330656A1/en not_active Abandoned
-
2023
- 2023-08-16 US US18/450,564 patent/US20230390269A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021503480A (ja) | 2021-02-12 |
| US20210330656A1 (en) | 2021-10-28 |
| AU2018367623A1 (en) | 2020-05-21 |
| US20200030307A1 (en) | 2020-01-30 |
| NZ764107A (en) | 2024-07-05 |
| EP3710000B1 (en) | 2025-04-23 |
| CN111343981A (zh) | 2020-06-26 |
| IL274541B1 (en) | 2024-06-01 |
| US20210093621A1 (en) | 2021-04-01 |
| SI3710000T1 (sl) | 2025-07-31 |
| KR20200088346A (ko) | 2020-07-22 |
| WO2019099883A1 (en) | 2019-05-23 |
| PT3710000T (pt) | 2025-05-29 |
| FI3710000T3 (fi) | 2025-07-03 |
| RU2020119259A (ru) | 2021-12-17 |
| AU2018367623B2 (en) | 2024-03-28 |
| CN119074729A (zh) | 2024-12-06 |
| KR102864285B1 (ko) | 2025-09-24 |
| IL274541B2 (en) | 2024-10-01 |
| EP3710000A1 (en) | 2020-09-23 |
| JP7306614B2 (ja) | 2023-07-11 |
| KR20250140655A (ko) | 2025-09-25 |
| BR112020009520A2 (pt) | 2020-11-03 |
| HUE071527T2 (hu) | 2025-09-28 |
| MX2020005167A (es) | 2020-08-20 |
| HRP20250615T1 (hr) | 2025-07-18 |
| US20230390269A1 (en) | 2023-12-07 |
| DK3710000T3 (da) | 2025-06-16 |
| ES3032138T3 (en) | 2025-07-15 |
| IL274541A (en) | 2020-06-30 |
| CA3081582A1 (en) | 2019-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020001290A1 (es) | Método para el tratamiento de enfermedades gastrointestinales con tradipitant. | |
| CY1123065T1 (el) | Ανασυνδυασμενα προβιοτικα βακτηριδια | |
| AR113881A1 (es) | Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia | |
| CL2019002304A1 (es) | Compuestos para el tratamiento del cáncer. | |
| MX2019012818A (es) | Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos. | |
| MX394062B (es) | Métodos para el tratamiento del cáncer ovárico. | |
| MX389468B (es) | Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña | |
| MX2017014191A (es) | Metodos de tratamiento de una enfermedad neurodegenerativa. | |
| CR20190375A (es) | Anticuerpos anti-tgf-beta y su uso | |
| MX2020005567A (es) | Metodos de tratamiento con asparaginasa. | |
| UY36905A (es) | Anticuerpos neutralizantes de poliomavirus | |
| CO2017001191A2 (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
| MX2017014375A (es) | Moduladores del ccr2. | |
| EA201890185A1 (ru) | Способы лечения опосредованных гепсидином нарушений | |
| MX388562B (es) | Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal. | |
| EA201891376A1 (ru) | Бензотиофеновые селективные блокаторы эстрогеновых рецепторов | |
| EA201890442A1 (ru) | Получение фоторецепторов для лечения заболеваний сетчатки | |
| CL2016000436A1 (es) | Método para el tratamiento de la enfermedad fibrótica | |
| TW201713333A (en) | Methods of treating a neurodegenerative disease | |
| MX2024004377A (es) | Tratamiento mejorado de la dermatitis atopica con tradipitant. | |
| MX2020008507A (es) | Metodo para producir 1,1,3,3-tetracloropropeno. | |
| AR110404A1 (es) | MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES FIBRÓTICAS UTILIZANDO EL INTERFERÓN-l | |
| CL2020002165A1 (es) | Uso de tradipitant para tratar la cinetosis. | |
| MX2017000467A (es) | Nuevo proceso para la purificacion de rhu-gcsf. | |
| MX2017007338A (es) | Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis. |